论文部分内容阅读
目的探讨抑癌基因PTEN与人错配修复基因hMSH2在宫颈癌中的表达及其与宫颈癌发生的关系。方法应用免疫组织化学方法检测34例正常宫颈、101例宫颈上皮内瘤样病变(CINI、CINII、CINIII)、46例宫颈癌等不同组织中PTEN与hMSH2的表达情况。结果PTEN蛋白在正常宫颈、CIN和宫颈癌各组组织中阳性表达率逐渐降低,其中宫颈癌组与其余各组比较差异均有统计学意义(P<0.01);CIN组与正常宫颈组间比较差异无统计学意义(P>0.05),CINIII组与CINI组比较,差异有统计学意义(P<0.05)。hMSH2在正常宫颈、CIN和宫颈癌各组组织中阳性表达逐渐增高,宫颈癌组与其余各组比较差异有统计学意义(P<0.01),CIN组与正常宫颈组比较,差异亦有统计学意义(P<0.01);CINIII组与CINI组比较差异有统计学意义(P<0.05)。宫颈癌组织中PTEN和hMSH2蛋白表达经Spearman相关分析,显示呈负相关关系(P<0.05)。结论PTEN和hMSH2在宫颈癌发生发展中发挥重要作用,联合检查可以作为宫颈癌筛查、早期诊断及基因治疗的指标之一。
Objective To investigate the expression of tumor suppressor gene PTEN and human mismatch repair gene hMSH2 in cervical cancer and its relationship with cervical cancer. Methods Immunohistochemistry was used to detect the expression of PTEN and hMSH2 in 34 cases of normal cervix, 101 cases of cervical intraepithelial neoplasia (CINI, CINII, CINIII) and 46 cases of cervical cancer. Results The positive expression rates of PTEN protein in normal cervical tissue, cervical intraepithelial neoplasia and cervical cancer tissues decreased gradually (P <0.01). The positive rates of cervical intraepithelial neoplasia in cervical cancer group were significantly different from those in other cervical cancer groups (P <0.01) The difference was not statistically significant (P> 0.05). There was significant difference between CINIII group and CINI group (P <0.05). The positive expression of hMSH2 in normal cervical tissue, CIN and cervical cancer tissues gradually increased, the difference between cervical cancer group and other groups was statistically significant (P <0.01), CIN group and normal cervical group, the difference was also statistically significant (P <0.01). There was significant difference between CINIII group and CINI group (P <0.05). The expression of PTEN and hMSH2 in cervical cancer tissues was negatively correlated by Spearman correlation analysis (P <0.05). Conclusions PTEN and hMSH2 play an important role in the development of cervical cancer. Combined examination can be used as one of the indicators of cervical cancer screening, early diagnosis and gene therapy.